Patents Examined by Scarlett Y Goon
-
Patent number: 11957716Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: January 14, 2022Date of Patent: April 16, 2024Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Ricarda Hannen, Jens Hukelmann, Florian Koehler, Daniel Johannes Kowalewski, Heiko Schuster, Oliver Schoor, Michael Roemer, Chih-Chiang Tsou, Jens Fritsche
-
Patent number: 11932694Abstract: Disclosed herein are anti-V-set domain containing T cell activation inhibitor 1 (VTCN1) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.Type: GrantFiled: April 19, 2018Date of Patent: March 19, 2024Assignee: Bluefin BioMedicine, Inc.Inventors: Ailan Guo, Svetlana Popova, Scott Michael Lonning, Jason G. Beaudet
-
Patent number: 11919963Abstract: Provided herein are VHH-containing polypeptides that bind CD123. Uses of the VHH-containing polypeptides are also provided.Type: GrantFiled: August 1, 2022Date of Patent: March 5, 2024Assignee: Inhibrx, Inc.Inventors: Chelsie Macedo, Kyle Jones, William Crago, Andrew Hollands, Milton Ma, John C. Timmer, Brendan P. Eckelman
-
Patent number: 11896619Abstract: The present disclosure relates to compounds (e.g., antibodies, antigen-binding fragments thereof, bispecific molecules, or chimeric antigen receptor polypeptides) that bind to a neoepitope of mutant nucleophosmin (NPM1c) in complex with, or presented by, a class I major histocompatibility complex (MHC class I) protein, or cells expressing such compounds, and their use in methods for treating, or ameliorating one or more symptoms of, cancer.Type: GrantFiled: January 8, 2021Date of Patent: February 13, 2024Assignee: Massachusetts Institute of TechnologyInventors: Jianzhu Chen, Guozhu Xie
-
Patent number: 11827716Abstract: Provided herein are D domain containing polypeptides that specifically bind targets of interest, as are nucleic acids encoding the D domain containing polypeptides, vectors containing the nucleic acids and host cells containing the nucleic acids and vectors. Also provided herein are methods of making and using the D domain containing polypeptides, nucleic acids, vectors and host cells, for example, but not limited to, in diagnostic and therapeutic applications. Also provided herein are multi-functional chimeric antigen receptor (CAR)-based compositions and Adapters and their use in methods of directing immune responses to target cells. In some embodiments, the methods include the use of a CAR expressing cell in combination with an Adapter. The Adapter confers the ability to modulate, alter, and/or direct CAR expressing cell-mediated immune response in vitro and in vivo.Type: GrantFiled: November 14, 2022Date of Patent: November 28, 2023Assignee: ARCELLX, INC.Inventors: David Lafleur, Jeffrey S. Swers, Justin Edwards
-
Patent number: 11802159Abstract: The present invention relates to compositions and methods for treating diseases, disorders or conditions associated with the expression of the glycosyl-phosphatidylinositol (GPI)-linked GDNF family protein ?-receptor 4 (GFR?4).Type: GrantFiled: September 29, 2020Date of Patent: October 31, 2023Assignees: The Trustees of the University of Pennsylvania, The Scripps Research InstituteInventors: Donald L. Siegel, Vijay Bhoj, Christoph Rader, Rebecca Goydel
-
Patent number: 11779649Abstract: This application discloses anti-PMEL17 antibodies, antigen binding fragments thereof, and antibody drug conjugates comprising antibodies or antigen binding fragments conjugated to a GNAQ/GNA11 inhibitor. The application also discloses methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.Type: GrantFiled: December 18, 2019Date of Patent: October 10, 2023Assignee: Novartis AGInventors: Matthew Burger, Joseph Anthony D'Alessio, Tony Fleming, Vivek Rauniyar, Eusebio Manchado Robles, Christian Kunz, Markus Waldhuber
-
Patent number: 11773151Abstract: The present disclosure provides recombinantly manufactured ultra-long acting insulin-Fc fusion proteins for use in treating canine and feline diabetes. The insulin-Fc fusion proteins comprise an insulin polypeptide linked via a peptide linker to an Fc-fragment of canine or feline origin. Based on the results obtained, creating a treatment that is amenable to low cost manufacturing, exhibits sufficient in vivo bioactivity, displays extended duration of bioactivity, does not induce anti-drug antibodies, and substantially retains is potency over multiple administrations, requires a non-obvious combination of insulin polypeptide, peptide linkers, and species-specific Fc fragment, in addition to selective mutations on one or more of these components. Exemplary ultra-long acting insulin-Fc fusion proteins, polynucleotides encoding these insulin-Fc fusion proteins, and pharmaceutical formulations of exemplary insulin-Fc fusion proteins are provided, in addition to methods of use and preparation.Type: GrantFiled: September 29, 2021Date of Patent: October 3, 2023Assignee: Akston Biosciences CorporationInventors: Thomas M. Lancaster, Todd C. Zion
-
Patent number: 11773162Abstract: The invention provides methods and compositions for the treatment of cancer using anti-Siglec7 antibodies.Type: GrantFiled: August 4, 2017Date of Patent: October 3, 2023Assignee: Allakos, Inc.Inventors: Christopher Bebbington, Wouter Korver, Nenad Tomasevic, Suzy El Bader, Kenneth Luehrsen
-
Patent number: 11718657Abstract: The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide SLLQHLIGL (SEQ ID NO: 1) derived from the germline cancer antigen PRAME. Said TCRs may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native PRAME TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.Type: GrantFiled: June 19, 2018Date of Patent: August 8, 2023Assignee: Immunocore LimitedInventors: Philip William Addis, Nicole Joy Bedke, Lucie Bouard, Stephen Harper, Nathaniel Liddy, Tara Mahon, Ronan Pádraic O'Dwyer
-
Patent number: 11718846Abstract: The invention provides a method of modifying a targeted site of a double stranded DNA, including a step of contacting a complex wherein a nucleic acid sequence-recognizing module that specifically binds to a target nucleotide sequence in a selected double stranded DNA and a nucleic acid base converting enzyme are linked, with the double stranded DNA, to convert one or more nucleotides in the targeted site to other one or more nucleotides or delete one or more nucleotides, or insert one or more nucleotides into the targeted site, without cleaving at least one strand of the double stranded DNA in the targeted site.Type: GrantFiled: February 14, 2020Date of Patent: August 8, 2023Assignee: NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITYInventors: Keiji Nishida, Akihiko Kondo, Satomi Kojima
-
Patent number: 11713348Abstract: The present disclosure relates to a scFv amino acid sequence capable of recognizing CD19 antigen and a nucleotide sequence encoding the same, and also relates to a chimeric antigen receptor, a nucleic acid encoding the same and a cell expressing the same, and their uses in the manufacture of a medicament for treating tumors. The chimeric antigen receptor of the present disclosure comprises at least one extracellular domain, an optional transmembrane domain and at least one intracellular costimulatory signaling domain, wherein the extracellular domain comprises a CD19 antigen-recognizing and binding domain. The chimeric antigen receptor of the present disclosure has been humanized, resulting in a longer survival period in vivo, and a corresponding extended complete remission period in patients.Type: GrantFiled: March 8, 2019Date of Patent: August 1, 2023Assignee: GUANGDONG ZHAOTAI INVIVO BIOMEDICINE CO., LTDInventors: Peng Li, Ruocong Zhao, Zhaoyang Tang, Le Qin, Yuanbin Cui, Simiao Lin, Yao Yao
-
Patent number: 11707533Abstract: The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.Type: GrantFiled: July 27, 2020Date of Patent: July 25, 2023Assignees: LegoChem Biosciences, Inc., ABL Bio, Inc.Inventors: Yun-Hee Park, Ho Young Song, Hyun Min Ryu, Sung Min Kim, Ju Yuel Baek, Ji Hye Oh, Nara Han, Hyoung Rae Kim, Kyung Eun Park, Hyeun Joung Lee, Ju Young Lee, Dae Hyuck Kang, Young-Jae Yang, Ji-Na You, Yong Zu Kim, Chang Sun Lee, Jeiwook Chae, Jinwon Jung, Juhee Kim, Bora Lee, Daehae Song, Byungje Sung, Donghoon Yeom, Jaehyun Eom, Youngeun Hong, Jinhyung Ahn, Yangsoon Lee, Kyungjin Park, Jiseon Yoo, Minji Park
-
Patent number: 11702661Abstract: The present invention provides for methods to obtain multiple information-rich samples at different time points from the same cell while minimally disrupting the cell. The subject matter disclosed herein is generally related to nucleic acid constructs for continuous monitoring of live cells. Specifically, the subject matter disclosed herein is directed to nucleic acid constructs that encode a fusion protein and a construct RNA sequence that induce live cells to self-report cellular contents while maintaining cell viability. The present invention may be used to monitor gene expression in single cells while maintaining cell viability.Type: GrantFiled: September 21, 2017Date of Patent: July 18, 2023Assignees: The Broad Institute, Inc., Massachusetts Institute of TechnologyInventors: Paul Blainey, Jacob Borrajo, Mohamad Najia, Atray Dixit
-
Patent number: 11690911Abstract: The present invention covers combinations of at least two components, component A and component B, comprising component A being an inhibitor of ATR kinase, particularly an inhibitor of ATR kinase selected from VX-803, VX-970, AZD-6738, a compound of general formula (I) described herein, a compound of general formula (Ib) described herein and Compound A described infra, and component B being a PD-1/PD-L1 inhibitor described herein. Another aspect of the present invention covers the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment of a hyper-proliferative disease.Type: GrantFiled: July 31, 2018Date of Patent: July 4, 2023Assignees: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventor: Antje Margret Wengner
-
Patent number: 11685729Abstract: The present invention relates to derivatives of formula (I) wherein Ring A, W, X, Y, Z, R1, R2, R3 and R4 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as C5a receptor modulators.Type: GrantFiled: January 18, 2019Date of Patent: June 27, 2023Assignee: IDORSIA PHARMACEUTICALS LTD.Inventors: Sylvie Froidevaux, Francis Hubler, Mark Murphy, Dorte Renneberg, Simon Stamm
-
Patent number: 11667709Abstract: Antibodies and antigen-binding fragments that bind to TIGIT are disclosed. The disclosure further relates to methods and compositions for use in treating an immune-related disease (e.g., a cancer or an infection or infectious disease) by administering a composition disclosed herein.Type: GrantFiled: September 23, 2020Date of Patent: June 6, 2023Assignee: Industrial Technology Research InstituteInventors: Min-Yuan Chou, Li-Tsen Lin, Chung-Yuan Sun, Ya-Ping Lai, Chin-Pen Lai, Ssu-Yuan Wu, Mei-Wei Lin
-
Patent number: 11634500Abstract: This invention relates to anti-CD73 antibodies and methods of using them in treating diseases and conditions related to CD73 activity, e.g., cancer.Type: GrantFiled: September 4, 2020Date of Patent: April 25, 2023Assignee: LES LABORATOIRES SERVIERInventors: Michael Monrad Grandal, Torben Gjetting, Johan Lantto, Janus Schou Jakobsen, Randi Westh Hansen, Camilla Fröhlich
-
Patent number: 11634729Abstract: Disclosed herein are modified strains for improving secretion of recombinantly expressed products secreted from a host organism with improved growth and productivity characteristics, as well as methods of using the modified strains.Type: GrantFiled: May 17, 2019Date of Patent: April 25, 2023Assignee: BOLT THREADS, INC.Inventor: Thomas Stevens
-
Patent number: 11578333Abstract: The invention relates to the production and use of Cas-encoding sequences and vectors comprising these. Aspects of the invention provide products, vectors, delivery vehicles, uses and methods for producing Cas-encoding sequences in bacterial or archaeal cells.Type: GrantFiled: March 8, 2021Date of Patent: February 14, 2023Assignee: SNIPR Biome ApSInventors: Virginia Martinez, Ruben Vazquez-Uribe, Adam Takos, Eric Van Der Helm, Jasper Clube